Publikationen (28) Publikationen, an denen Forscher/innen teilgenommen haben

2024

  1. Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)

    Clinical and Translational Oncology

  2. Detection of Carcinoma-Associated Fibroblasts Derived from Mesothelial Cells via Mesothelial-to-Mesenchymal Transition in Primary Ovarian Carcinomas

    Cancers, Vol. 16, Núm. 15

  3. Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment

    Infectious Diseases, Vol. 56, Núm. 7, pp. 575-580

2023

  1. Correlation Between Opioid Drug Prescription and Opioid-Related Mortality in Spain as a Surveillance Tool: Ecological Study

    JMIR public health and surveillance, Vol. 9, pp. e43776

  2. Outcomes and clinical characteristics of the compassionate use of plitidepsin for immunocompromised adult patients with COVID-19

    International Journal of Infectious Diseases, Vol. 135, pp. 12-17

  3. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

    Cancer Treatment and Research Communications, Vol. 37

  4. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2647-2664

  5. Targeting carcinoma-associated mesothelial cells with antibody–drug conjugates in ovarian carcinomatosis

    Journal of Pathology, Vol. 261, Núm. 2, pp. 238-251

  6. Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement

    eClinicalMedicine, Vol. 60

2022

  1. Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer

    Frontiers in Oncology, Vol. 12

  2. Flipped Inflammatory Time and the Role of Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2: Optimizing Tocilizumab Against Coronavirus Disease 2019

    The Journal of infectious diseases, Vol. 226, Núm. 1, pp. 1-5

  3. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

    Nature Communications, Vol. 13, Núm. 1

  4. Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia

    Journal of Hematology and Oncology

  5. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

    European Journal of Cancer, Vol. 161, pp. 26-37

2021

  1. MRI guided ROLL/SNOLL in breast cancer patients treated with neoadjuvant chemotherapy

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 40, Núm. 2, pp. 91-99

  2. Mesothelial‐to‐mesenchymal transition and exosomes in peritoneal metastasis of ovarian cancer

    International Journal of Molecular Sciences, Vol. 22, Núm. 21

  3. Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy

    Annals of Oncology

2020

  1. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)

    EClinicalMedicine, Vol. 28

  2. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

    Breast Cancer Research, Vol. 22, Núm. 1

  3. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292